Welcome to our dedicated page for Aligos Therapeutics news (Ticker: ALGS), a resource for investors and traders seeking the latest updates and insights on Aligos Therapeutics stock.
Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California, and founded in 2018. The company is dedicated to developing novel therapeutics to address unmet medical needs in liver and viral diseases. Aligos is particularly focused on treatments for chronic hepatitis B (CHB) and metabolic dysfunction-associated steatohepatitis (MASH), as well as for coronaviruses.
The company’s lead candidate, ALG-010133, is a synthetic oligonucleotide currently in Phase I clinical trial for the treatment of CHB. Other promising candidates in their pipeline include ALG-000184, a capsid assembly modulator also targeting CHB, and ALG-055009, a small molecule thyroid hormone receptor beta (THR-ß) agonist for MASH. Initial studies on ALG-055009 have demonstrated enhanced potency and favorable pharmacokinetics.
Aligos is advancing its clinical programs, including the Phase 2a HERALD study of ALG-055009, which will assess the safety and efficacy of the drug in subjects with MASH, with topline data expected in Q4 2024. The study aims to enroll about 100 subjects and will evaluate multiple non-invasive biomarkers to track liver health improvements.
The company is also actively engaged in collaborations and partnerships to bolster its research efforts. Recently, Aligos presented positive data at the European Association for the Study of the Liver (EASL) Congress 2024, showcasing the sustained antiviral activity of ALG-000184 in both HBeAg-positive and HBeAg-negative CHB subjects. This data represents a significant advancement in viral load suppression and demonstrates Aligos' potential to deliver best-in-class treatments.
Besides its focus on liver diseases, Aligos is developing ALG-097558, a pan-coronavirus protease inhibitor showing promise in preclinical and early clinical trials. ALG-097558 has been well tolerated and does not require ritonavir boosting, addressing a critical need for effective, easily administered antiviral therapies.
Financially, Aligos reported cash, cash equivalents, and investments totaling $112.7 million as of March 31, 2024. The company continues to secure funding to support its operations and further its research projects, with a belief that its current cash balance will sustain operations through the end of 2025.
Aligos’ mission is to leverage its deep expertise and innovative approaches in drug development to become a leader in treating liver and viral diseases, ultimately improving patient outcomes and addressing high unmet medical needs worldwide.
Aligos Therapeutics (ALGS) has announced significant progress in its clinical trial for chronic hepatitis B (CHB) treatment. The company has completed single ascending doses of its antisense oligonucleotide, ALG-020572, in healthy volunteers and has initiated the multiple ascending dose (MAD) phase in CHB patients, with the first patient dosed. The study aims to evaluate the safety and effectiveness of ALG-020572 with results expected to be presented at a future conference. Aligos is committed to developing innovative antiviral therapies targeting unmet medical needs in liver diseases.
Aligos Therapeutics (Nasdaq: ALGS) announced an expansion of its collaboration with Merck to develop oligonucleotide therapies targeting non-alcoholic steatohepatitis (NASH). This expanded agreement allows Merck to in-license a second NASH target and potentially add a third target in the cardiometabolic space. Aligos will receive payments for these licenses and could earn up to $460 million in milestones plus royalties. The collaboration underscores Aligos' strengths in oligonucleotide research, aiming to create effective therapies for unmet medical needs.
Aligos Therapeutics has announced the discontinuation of its ALG-010133 drug candidate for chronic hepatitis B (CHB) after Phase 1 data indicated insufficient antiviral activity. At the target dose of 400 mg, there was no significant reduction in HBsAg levels. Attempts to evaluate higher doses were deemed unlikely to meet the required efficacy benchmarks. Despite this setback, Aligos emphasizes its robust pipeline, with candidates like ALG-000184 and ALG-020572 still in development, aiming for enhanced functional cure rates in CHB.
Aligos Therapeutics, Inc. (Nasdaq: ALGS) announced that CEO Lawrence M. Blatt will present at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 5:15 pm ET. The presentation, conducted virtually, will include a Q&A session. An audio webcast of the presentation will be accessible through the Aligos investor section on their website. Aligos is focused on developing therapeutics for unmet medical needs in viral and liver diseases, particularly targeting chronic hepatitis B and nonalcoholic steatohepatitis.
Aligos Therapeutics (Nasdaq: ALGS) has commenced dosing in healthy volunteers for its Phase 1 trial, Study ALG-055009-301, evaluating its THR-b agonist candidate, ALG-055009, aimed at treating nonalcoholic steatohepatitis (NASH). This cohort study seeks to assess the drug's safety, tolerability, and pharmacodynamics. Dosing in subjects with mild hyperlipidemia is expected to begin in Q1 2022, with topline data anticipated by Q3 2022. NASH currently lacks approved treatments, and Aligos aims to address this significant medical need.
Aligos Therapeutics (Nasdaq: ALGS) has revealed promising new data for its chronic hepatitis B (CHB) treatments at the HEP DART meeting. The Phase 1b study of ALG-000184 demonstrated a high reduction of HBV DNA and RNA in HBeAg-positive patients, similar to results in HBeAg-negative groups. Additionally, preliminary data on a new oral PD-1/PD-L1 antagonist underscores its potential in enhancing immune responses against HBV. Aligos aims to develop a combination therapy approach for functional cures in CHB patients, leveraging various therapeutic candidates.
On November 23, 2021, Vipergen announced a multi-target drug discovery agreement with Aligos Therapeutics (Nasdaq: ALGS). This collaboration utilizes Vipergen's DNA-encoded library (DEL) technology to discover small-molecule compounds targeting specific proteins developed by Aligos for treating viral and liver diseases. Aligos will maintain exclusive rights for global commercialization of any resulting products. Financial details remain undisclosed, but Vipergen aims to enhance Aligos' drug portfolio, addressing critical health needs in chronic hepatitis B, NASH, and coronavirus.
Aligos Therapeutics (Nasdaq: ALGS) announced that Lawrence M. Blatt, Ph.D., MBA, Chairman and CEO, will present at the Piper Sandler 33rd Annual Virtual Healthcare Conference from November 30 to December 2, 2021. The presentation will be available as a webcast starting November 22, 2021, at 10:00 AM EST, with a replay accessible for 90 days. Aligos management will also hold virtual investor meetings during the conference. For more details, visit the Aligos website or contact your Piper Sandler representative.
Aligos Therapeutics, Inc. (Nasdaq: ALGS) announced the appointment of Dr. Bridget Martell to its board of directors. Dr. Martell brings extensive experience in therapeutics development, having contributed to six marketed products and held leadership roles in various biopharmaceutical companies. CEO Lawrence Blatt emphasized her role in advancing Aligos's therapeutic candidates for chronic hepatitis B and NASH through clinical trials. Aligos aims to be a leader in treating viral and liver diseases with innovative therapies.
On November 15, 2021, Aligos Therapeutics announced that CEO Lawrence M. Blatt will present at the Jefferies London Healthcare Conference on November 18-19, 2021. The company, listed on Nasdaq under the ticker ALGS, focuses on developing innovative treatments for viral and liver diseases. A webcast of the presentation will be available starting November 18, 2021, at 8:00 AM GMT with a replay accessible for 30 days. Interested investors can schedule virtual one-on-one meetings through their Jefferies representatives.
FAQ
What is the current stock price of Aligos Therapeutics (ALGS)?
What is the market cap of Aligos Therapeutics (ALGS)?
What does Aligos Therapeutics focus on?
What is Aligos Therapeutics’ lead drug candidate?
What recent achievements has Aligos Therapeutics made?
What is the Phase 2a HERALD study?
How is Aligos Therapeutics funded?
Where is Aligos Therapeutics headquartered?
When was Aligos Therapeutics founded?
What is ALG-097558?
What are the financial results for Aligos Therapeutics’ first quarter 2024?
What is the mission of Aligos Therapeutics?
